Introduction Qualifying active pharmaceutical ingredient (API) vendors and contract manufacturing organizations (CMOs) requires Nitrosamine Risk Assessment Services for API Suppliers […]
Introduction Nitrosamine Testing for Peptide and GLP-1 drug products requires a comprehensive evaluation of synthetic-route risks, peptide-specific sample preparation, and
Nitrosamine Testing for Peptide and GLP-1 Drug Products: Specialized CRO Services Read More »
Introduction Selecting a qualified Nitrosamine Testing Laboratory in Canada requires verification of active Drug Establishment Licence (DEL) compliance, highly sensitive
Introduction Forced Degradation Studies in CMC serve as the mechanistic engine of a defensible pharmaceutical impurity control strategy, linking intrinsic
Forced Degradation Studies in CMC: Building a Robust Impurity Control Strategy Read More »
Introduction Under the harmonized ICH M10 guideline, which was adopted at Step 4 on May 24, 2022, issued by the
Introduction Effective Calibration Curve Design and Regression Weighting in LC-MS/MS bioanalysis requires matching the mathematical order of the calibration function
Introduction: Polymorphism solid-state characterization CMC work answers one regulatory question: is the crystal form of your drug substance known, stable
Introduction: The ICH Q11 CMC drug development guidelines, read together with ICH Q8(R2), explain how sponsors should design, justify and
ICH Q11 and Q8 Guidelines in CMC Drug Development: A Practical Overview for Sponsors Read More »
Introduction: Choosing among CMC consulting services for biotech startups comes down to one question: which partner can turn your science
CMC Consulting Services for Biotech Startups: How to Choose the Right CRO Partner Read More »
Introduction Understanding Peptide CDMO Cost / Pricing in the United States involves examining a complex financial landscape in which preclinical
How Much Does Peptide Manufacturing Cost with a US CDMO? Read More »
